We are live on ! Find out more

Altimmune

ALT

Market cap $416M

2.14 USD

+0.04

1.9%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

2.14

0.00

0%

1 day

1.9%

5 days

-0.93%

1 month

-27.95%

3 months

-26.71%

6 months

-18.63%

Year to date

-39.03%

1 year

-46.5%

5 years

-80.19%

10 years

-99.74%

About: Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 57

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 7.1%

Neutral 85.7%

Negative 7.1%

Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, Mitchel Sayare, Ph.D.

Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide GAITHERSBURG, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new clinical and preclinical data on pemvidutide will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or ALD.

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

Altimmune to Participate in Stifel Cardiometabolic Forum

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.

Altimmune to Participate in Stifel Cardiometabolic Forum

Zacks Investment Research

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Zacks Investment Research

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

Zacks Investment Research

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

Zacks Investment Research

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™